Welcome Day 3 and Challenges of Osteoporosis Care during Covid-19: A Global Perspective

Welcome Day 3

Join Dr. Rachel Pessah-Pollack, MD, FACE, Vice-Chair ISCD 2022 Annual Meeting Planning Committee when she presents the day's highlights.

Challenges in 2022 Osteoporosis Care

Session approved for 1.5 ASRT Category A Credit

This session duration is 80 minutes.

Learning Objectives:

  • Discuss the impact of COVID Pandemic on Osteoporosis
  • Describe the challenges for osteoporosis care during the COVID Pandemic
  • Recognize the limitations of Osteoporosis treatment during a global pandemic

Angela M. Cheung, MD, PhD, FRCPC

ISCD Canadian Panel Chair

University of Toronto, CANADA

Dr. Angela M. Cheung is Professor of Medicine, KY and Betty Ho Chair of Integrative Medicine at University of Toronto (UT) and Senior Physician Scientist at University Health Network (UHN). She is the Founding Director of University Health Network Osteoporosis Program and the Founding Director of University of Toronto Centre of Excellence in Skeletal Health Assessment (CESHA). She currently holds a Tier 1 Canada Research Chair in Musculoskeletal and Postmenopausal Health, and has held a Canadian Institutes of Health Research (CIHR) Senior Investigator award, the Canadian Society of Internal Medicine (CSIM) David Sackett Senior Investigator award, the Ontario Premier Research Award and the University of Toronto Eudenie Stuart Mentorship award and the Michael Hutcheon Mentor of the Year award. She is chair of the International Society of Clinical Densitometry Canadian Panel, member of International Osteoporosis Foundation Council of Scientific Advisors, member of Endocrine Society Clinical Guidelines Committee, and past chair of Osteoporosis Canada Scientific Advisory Council. She obtained her M.D. from Johns Hopkins University School of Medicine in 1988, and her PhD from Harvard University in 1997. She is a Fellow of the Royal College of Physicians of Canada and has been in clinical practice for >30 years. Twitter @AngelaMCheung

Disclosures: 

Amgen (Self) : Advisory Board (Status: Ongoing); Paladin Labs Inc. (Self) : Advisory Board (Status: Ongoing)

Wing P. Chan, MD

ISCD Asia Pacific Panel chair, Scientific Advisory Council chair, BOD member

Wan Fang Hospital, Taipei Medical University

Dr. Wing P. Chan is Professor and Chief of the Department of Radiology at Wan Fang Hospital, Taipei Medical University, Taiwan. Currently, he is the Taiwan Radiological Society president, Taiwanese Osteoporosis Association honorary consultant, ISCD Asia Pacific Panel chair, Scientific Advisory Council chair, BOD member, and IOF/ISCD Joint Osteoporosis Essentials Course faculty. He earned his medical degree from Taipei Medical University and completed his residency at National Taiwan University Hospital. In 1989 he completed a Musculoskeletal Radiology research fellowship at UCSF and stayed until 1992 as a visiting assistant professor. He subsequently served as a staff radiologist at Sun Yat-Sen Cancer Center in Taiwan. Dr. Chan is a founding convener of the Musculoskeletal Radiology committee, DXA Quality and Osteoporosis Education committee, and Safety and Quality committee of the Taiwan Radiological Society. Dr. Chan implemented a series of strategies to improve osteoporosis detection in Taiwan, finding a prevalence of osteoporosis close to 30% in Taiwanese postmenopausal women. Dr. Chan also established the mandatory DXA and Osteoporosis - Prerequisite Course for Taiwanese Radiology Residency Programs. Further, Dr. Chan developed quality improvement DXA best practices for technologists during scan acquisition and analysis. He instituted a standardized automated DXA reporting system to reduce reporting errors. In 2013, Dr. Chan was the first physician to receive The National Best Teacher Award from the Ministry of Education in Taiwan. Dr. Chan has served as editor of 7 books and author or co-author of 40 book chapters and invited articles. He has also authored over 230 articles in peer-reviewed medical journals.

Disclosures: No relationships to disclose.

Hao Xu, MD

ISCD China Panel

The First Affiliated Hospital of Jinan University Department of Nuclear Medicine

Xu Hao, MD, Professor, chief physician. Director of medical imaging department and director of nuclear medicine discipline of the First Affiliated Hospital of Jinan University. He has been engaged in nuclear medicine diagnosis and treatment, osteoporosis and bone mineral density measurement clinical and scientific research for more than 30 years, and has published more than 200 professional papers and more than 10 professional works.

Disclosures: No relationships to disclose.

Carmen Gabriela Barbu, MD,PhD,CCD

Associate Professor of Endocrinology

Carol Davila University of Medicine and Pharmacy, Bucharest, Romania

Carmen Gabriela Barbu MD, PhD, CCD,Associate Progessor of Endocrinology, Elias Hospital Endocrinology Department, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania Career path and relevant experience: PhD title earned at the “Carol Davila” University of Medicine and Pharmacy, Bucharest. Title of thesis: “Bone mineral density and biochemical bone turnovers in glucocorticoid osteoporosis” Ph. D title confirmed in 2004. I had training in dual X ray absorbtiometry (DXA) for bone density evaluation (ISCD certification in 2005), bone related molecular biology and genetic studies (European Federation of Endocrine Society, Como, Italy 2000 and University of Aberdeen, UK, 2002), clinical research, project management, ultrasound evaluation in endocrinology, pediatric endocrinology and other endocrinology related specific fields. Since 2006 I am International Society for Clinical Densitometry full faculty member, as lecturer for international courses in bone densitometry, since 2013 I am faculty for the IOF-ISCD Osteoporosis Essentials courses. In 2010 I became member of an international workgroup for communication in healthcare (tEACH), in 2012 was a member of the ISCD working group for body composition consensus development. I was project manager for three national funded research grants and member in the research team in 8 national research projects,I am actually memeber of the Endocrinology National Comitee as an advisory board for Minister of Health in Romania

Disclosures: 

Amgen (Self) : Advisory Board (Status: Terminated --- 2021); Eli Lilly (Self) : Advisory Board (Status: Terminated --- 2020); Stada (Self) : speaker fee (Status: Terminated --- 2022); Theramex (Self) : Independent Contractor (Status: Terminated --- 2022)

Henrique P. Arantes, CCD

ISCD Latin America Panel

IMEPAC ARAGUARI

HENRIQUE PIEROTTI ARANTES, MD, PhD, CCD. HENRIQUE IS A PHYSICIAN, SPECIALIZED IN ENDOCRINOLOGIST AND COMPLETED HIS MASTERS AND PhD IN BONE METABOLISM. COORDINATOR OF THE DEPARTMENT OF BONE DENSITOMETRY AT ABRASSO (2021-2022) AND LATIN AMERICAN REGIONAL PANEL REPRESENTATIVE AT ISCD (5/2/2020 - 5/2/2023). HIS CURRENT ROLE IS A COORDINATOR OF THE MEDICAL COURSE AT IMEPAC ARAGUARI - MG - BRAZIL AND CLINICAL DENSITOMETRIST.

Disclosures: No relationships to disclose.

Robert Wermers, Doctor

Consultant and Chair Division of Endocrinology, Diabetes, Metabolism and Nutrition

Mayo Clinic, Rochester, Minnesota U.S.A.

ROBERT WERMERS, M.D. is a Professor of Medicine at the Mayo Clinic College of Medicine and Science and a Consultant in the Division of Endocrinology, Diabetes, Metabolism, and Nutrition at the Mayo Clinic in Rochester, Minnesota. Dr. Wermers obtained his undergraduate degree from the University of Nebraska in Lincoln, Nebraska and his Doctor of Medicine from the University of Nebraska Medical Center in Omaha, Nebraska. He completed his training in internal medicine training and fellowship in Endocrinology at the Mayo Clinic in Rochester, Minnesota. Dr. Wermers clinical interests include metabolic bone disease and transplant endocrinology. His research has focused on metabolic bone disorders including primary hyperparathyroidism, hypercalcemia, Paget’s disease of bone, osteoporosis, and other metabolic bone diseases. Dr. Wermers is chair of the Division of Endocrinology, Diabetes, Metabolism and Nutrition at the Mayo Clinic Rochester. He is also chair of the Enterprise Pharmacy and Therapeutics Committee and Mayo Clinic Midwest Pharmacy and Therapeutics Committee.

Disclosures: No relationships to disclose.

Susan van der Kamp, RGN CDT

Clinical nurse Clinical Nurse Specialist

Consultant

Susan van der Kamp Susan van der Kamp RGN CDT graduated from St. Vincent’s University Hospital, Dublin, Ireland (cum laude) in 1975 in which hospital in 1994 she formed part of a team that established a DXA service as part of a multi-disciplinary bone health service. Her role in scanning patients as a technologist was in combination with the setting up and running of a number of pharmaceutical clinical trials. Susan became co-director of the newly established DXA unit in 2005. In 2006 Susan conducted a national audit of DXA services in Ireland, which was pivotal in assessing the need for DXA standard setting across the island of Ireland. Susan set up bimonthly workshops in 2007 with 5 other DXA units in Dublin where DXA issues and bone health matters were discussed. Susan was part of the National Steering Group on the Prevention of Falls and Fractures in Ireland’s Ageing Population 2008. 2012 Susan established a paediatric DXA service. Susan set up a DXA fracture liaison service (FLS) in 2016 and became part of a multidisciplinary FLS group, comprising disciplines from orthogeriatric, orthopaedic surgery, emergency department, physiotherapy, occupational health, dietetics and nursing. This comprised of monthly meetings of the MDT group. In 2017 Susan set up ‘Capture the Fracture’ which achieved a bronze star. Her achievements in the fracture liaison service were recognised in Oxford, UK in 2018 through a top poster winning competition. The emphasis and high regard for practical quality standards in DXA scanning throughout Susan’s career has been demonstrated by winning a number of international awards as well as close communications with the providers of equipment for DXA scanning. She is particularly interested in precision studies to improve and maintain quality standards of which she has completed several in the course of her career. In 2020 Susan retired from public service. Since that time she is working in two private clinics providing DXA services. She continues to emphasise the necessity to maintain strict quality standards and is currently involved in leading a precision study in one of these units. In addition, she provides consultancy to (HSL) Hospital Services Limited in providing training to DXA scanning staff on Hologic installations throughout the island of Ireland. She is one of the founding members of the Irish DXA Society established in 2018 and as a current Board Member is involved in training courses and lectures for staff carrying out DXA scans in both private and public medical service. Recently the national Nursing and Midwifery Board has invited Susan to advise on training requirements for nursing staff involved in DXA scanning. Susan, as a DXA technologist for which she has won a number of international awards (2013, 2015, 2018) in summary is highly motivated and throughout her work in this area has demonstrated leadership at local and national level.

Disclosures: No relationships to disclose.

Rachel Pessah-Pollack, FACE

Clinical Associate Professor

NYU Langone Hospitals

Rachel Pessah-Pollack, M.D., F.A.C.E. is a Clinical Associate Professor of Medicine in the Division of Endocrinology, Diabetes & Metabolism at NYU Langone Health in New York City. She trained at the Mount Sinai School of Medicine in New York City, where she completed her Internal Medicine Residency and Endocrinology Fellowship and is Board Certified in Endocrinology, Diabetes & Metabolism. She was elected in 2019 to the American Association of Clinical Endocrinologists (AACE) Board of Directors for a three-year term. She has served as Chair of the AACE Clinical Practice Guidelines Oversight Committee and Chair of the AACE Women's Leadership Dinner in 2019. She served as Chair of the American College of Cardiology's (ACC) Diabetes Collaborative Registry Stakeholder Advisory Committee from 2018-2019. She has been named a New York Times Super Doctor (2017-2019) and New York Times Super Doctor Rising Star (2014-2016.) She is a frequent contributor to Health Monitor publications for patients and is on the Advisory Board of Endocrine Today. She is a coauthor of numerous peer-reviewed articles and clinical practice guidelines including the recently published AACE Postmenopausal Osteoporosis Guidelines. Dr. Pessah-Pollack specializes in metabolic bone disease and lectures nationally on the topic of postmenopausal osteoporosis. She remains actively involved in medical education and the training of endocrine fellows.

Disclosures: 

Boehringer Ingelheim/Eli Lilly (Self) : Advisory Board (Status: Ongoing); Health Monitor (Self) : Advisory Board (Status: Ongoing); Radius (Self) : Advisory Board (Status: Terminated --- 6/2020); Sanofi (Self) : Advisory Board (Status: Terminated --- 6/2020)

Key:

Complete
Failed
Available
Locked
Recorded Archive
Select the "View On-Demand Recording" button to begin.
Select the "View On-Demand Recording" button to begin.
Session
04/02/2022 at 8:00 AM (EDT)   |  85 minutes
04/02/2022 at 8:00 AM (EDT)   |  85 minutes
Survey
10 Questions
Medical Certificate
Up to 1.50 medical credits available  |  No certificate available
Up to 1.50 medical credits available  |  No certificate available